Patient P-01598

Synthetic patientNBL-101 · Day 109 · 25–34 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

75%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 58 GI-04 recommended — GI Support Protocol GI-04
Day 59 Patient accepted — Started GI-04 in the companion
Day 67 No meaningful change — GI Support Protocol GI-04
Day 69 ME-01 recommended — Monitoring Escalation ME-01
Day 70 Patient accepted — Started ME-01 in the companion
Day 73 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Nutritional resilience-7
Treatment adherence+7
GI instability+3
Toxicity-2

What helped?

GI Support Protocol GI-04Day 58
Result: no meaningful change
Monitoring Escalation ME-01Day 69
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

58%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 38/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 72 bpm
- WearableShort sleep window
Mucosal barrier integrity ↓30
- Daily logGI symptom score 61 and rising
- WearableSleep 5.4 h, below personal baseline
Inflammatory signalling ↑25
- BloodInflammatory load index 55

DNA

Fictional pharmacogenomic panel

CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2 · butyrate capacity 38/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 55 ms
Sleep: 5.4 h
Steps: 7,088
Resting HR: 68 bpm

Daily log: GI score 61, nutritional resilience 35, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01328	57%	S14	SC-12	no change	49
P-01675	57%	S14	NP-02	improved	38
P-01389	54%	S14	SC-12	improved	46
P-01494	54%	S14	GI-04	improved	42
P-01834	54%	S14	NP-02	improved	44
P-01413	53%	S14	GI-04	improved	44
P-01845	53%	S14	NP-02	improved	47
P-01891	53%	S14	SC-12	improved	41
P-01531	52%	S14	ME-01	improved	51
P-01412	50%	S14	NP-02	improved	49
P-01433	50%	S14	GI-04	improved	48
P-01436	50%	S14	GI-04	improved	38